Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifekalant-optimized radiofrequency ablation for persistent atrial fibrillation
ChiCTR2300073663Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nifekalant in Atrial fibrillation (AFib) (2 arms), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Atrial fibrillation recurrence. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
nifekalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR2300073663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073663.